Evidence Hub

Levagen+ (palmitoylethanolamide) alleviates joint pain and reduces the impact of joint pain in canines and felines: a double-blind, placebo-controlled, randomized clinical trial

Briskey D, Craddock E, Rao A, Mills PC

Frontiers in veterinary science, 2026

Abstract

Introduction: This study assessed the effectiveness of Levagen+ (palmitoylethanolamide), a fatty acid amide and lipid mediator, for both the alleviation and impact of joint pain, in canines and felines.

Methods: This prospective double-blinded, randomized placebo-controlled study supplemented 50 canines and 50 felines experiencing joint pain daily for 6 weeks with either Levagen+ or a placebo taken orally. Efficacy was determined in canines using the Canine Brief Pain Index (CBPI) and in felines using the Feline Musculoskeletal Pain Index (FMPI), both completed by owners at baseline, week 2, week 4 and week 6. Data were analyzed with distribution-appropriate tests and a two-way repeated-measures ANOVA to assess group, time, and interaction effects across outcomes.

Results: In canines, significantly more were classified as successfully treated in the Levagen+ group compared to the placebo group (76% vs. 40%; p p p p p < 0.05)]. Levagen+ was well tolerated in both species.

Discussion: These findings supported the hypothesis that Levagen+ reduces the impact of joint pain in companion animals.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free